Exton, Feature
Exton Company Finds Possible Alternative Treatment for Crohn’s Disease
Results from an international multi-center Phase II clinical trial suggest that extracorporeal photopheresis (ECP) may be effective in treating patients with clinically active (OR symptomatic) Crohn's disease who cannot tolerate or are refractory to immunosuppressants and/or anti-TNF agents.
Exton, Feature
Exton Company Finds Possible Alternative Treatment for Crohn’s Disease
Posted on 11 February 2011
Results from an international multi-center Phase II clinical trial suggest that extracorporeal photopheresis (ECP) may be effective in treating patients with clinically active (OR symptomatic) Crohn's disease who cannot tolerate or are refractory to immunosuppressants and/or anti-TNF agents. Continue Reading
Exton, Feature
New Software To Assist Sensors in Imaging
Posted on 24 January 2011
Exton-based Analytical Graphics, Inc. today introduced STK/EOIR—commercial modeling and simulation software for electro-optical infrared sensors used in space surveillance, missile defense and Earth remote sensing. Developed for use with AGI’s STK analysis and visualization software, STK/EOIR models sensor detection, tracking and imaging performance. It allows users with a basic understanding [...] Continue Reading
Exton, Feature
Kensey Nash Makes Partnership For Better Sports Surgery Results
Posted on 04 January 2011
Kensey Nash Corporation, a regenerative medicine company, announced it has entered into a manufacturing agreement with, and made a minority equity investment in, Orteq Sports Medicine, a medical device company specializing in the field of biodegradable polymer technology for meniscus repair. Continue Reading
Exton, Feature
Exton MS Patients Now Have Better Options For Relief
Posted on 11 December 2010
Physiotherapy Associates, the nation's foremost provider of outpatient rehabilitation services, announced its new MS Specialty Program, which includes physical therapy services and a health and wellness program designed to reduce or alleviate the symptoms of MS for patients, available in its more than 600 clinics throughout the United States. Continue Reading
Exton, Feature
Local Company Accepts US-Korea Free Trade Agreement
Posted on 09 December 2010
Analytical Graphics, Inc. (AGI) today welcomed the progress that U.S. and Korean negotiators have made in advancing the U.S.-Korea Free Trade Agreement (KORUS FTA) and supported the President's efforts to quickly gain Congressional ratification. AGI is the producer of software applications and development kits for integrated analysis of space, defense and intelligence systems. Continue Reading
Exton, Feature
Lottery Ticket Sales to Rise With New Partnership
Posted on 07 December 2010
Governor Edward G. Rendell today announced a new partnership with the Wawa convenience store chain that will significantly expand the Pennsylvania Lottery network and boost ticket sales by as much as $37 million annually. Continue Reading
Exton, Feature
Governor Rendell Approves of Revenue Estimates
Posted on 01 December 2010
Governor Edward G. Rendell today lauded the work of the state Budget Office and Department of Revenue for the accuracy of their revenue projections. This fiscal year, revenue collections in every month but September have been within less than one-half of one percent of the estimates certified by the Budget Office and Department of Revenue. Continue Reading
Exton, Feature
Research Group Releases Results of Kidney Study
Posted on 29 November 2010
BioTrends Research Group, Inc. released ChartTrends®: Renal Anemia in Chronic Kidney Disease Non-Dialysis (CKD-ND), an annual syndicated publication based on patient and laboratory data collected from over 1,000 US CKD-ND patient charts. ChartTrends® compare what physicians self-report about disease management to what actually occurs at the patient level. This report evaluates the management of renal anemia including patient characteristics, demographics, lab values, co-morbidities and concomitant medications that drive both decisions to treat and brand selection of erythropoietin stimulating agents (ESAs) and intravenous (IV) iron. Brand use dynamics such as dosing (including dosing interval and titration), persistency, administration location, brand switching and reasons for switching are also evaluated. Continue Reading
-
CATEGORIES
- Exton (41)
- Feature (35)
- Business (2)
- General (2)
- Pennsylvania (1)
-
ARCHIVES
- February 2011 (1)
- January 2011 (2)
- December 2010 (4)
- November 2010 (8)
- October 2010 (13)
- September 2010 (3)
- August 2010 (3)
- July 2010 (7)
- June 2010 (1)
Copyright © extonnews.com.Original News Theme by 
.